COST-EFFECTIVENESS OF PEMBROLIZUMAB (KEYTRUDA (R)) IN COMBINATION WITH CHEMOTHERAPY FOR FIRST-LINE TREATMENT OF METASTATIC SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) IN FRANCE-MedSci.cn

COST-EFFECTIVENESS OF PEMBROLIZUMAB (KEYTRUDA (R)) IN COMBINATION WITH CHEMOTHERAPY FOR FIRST-LINE TREATMENT OF METASTATIC SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) IN FRANCE

Chouaid, C; Bensimon, L; Tardu, J; Millier, A; Insinga, R; Rai, A; Levy-Bachelot, L; Levy, P

VALUE IN HEALTH, 2020; 23 (): S433

科室
- - 订阅+
  - 更多科室
工具
服务